Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex

This article was originally published in The Pink Sheet Daily

Executive Summary

Q3 results were strong, thanks to Avonex, but new competition from Novartis' oral MS therapy Gilenya and dwindling Rituxan royalties from Roche threaten longer-term outlook.

You may also be interested in...



Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound

In the second quarter, Biogen demonstrated a continuing ability to milk revenue from established MS products while it prepares to launch a wave of potentially market-shifting NMEs.

Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule

In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.

Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule

In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.

Related Content

Topics

UsernamePublicRestriction

Register

PS071362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel